<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="sleeping to severe complications such as depression, psychosis, and painful" exact="peripheral neuropathy," post="side effects which may necessitate discontinuation of treatment. The"/>
 <result pre="reverse transcriptase inhibitors, which are associated with the development of" exact="peripheral neuropathy" post="after prolonged use (an effect strongly associated with older"/>
 <result pre="transcriptase inhibitors, which are associated with the development of peripheral" exact="neuropathy" post="after prolonged use (an effect strongly associated with older"/>
 <result pre="occur and manage them appropriately. central nervous system antiviral efavirenz" exact="peripheral neuropathy" post="monoamine oxidase The content published in Cureus is the"/>
 <result pre="and manage them appropriately. central nervous system antiviral efavirenz peripheral" exact="neuropathy" post="monoamine oxidase The content published in Cureus is the"/>
 <result pre="side effects include flu-like symptoms and hematologic abnormalities such as" exact="anemia" post="and neutropenia. Moreover, some antiviral drugs cause significant neuropsychiatric"/>
 <result pre="but also discuss, in some cases, peripheral neurotoxicities such as" exact="neuropathy" post="and myopathy. By being aware of the neuropsychiatric side"/>
 <result pre="independently by all authors. Neuropsychiatric effects of antiviral therapy in" exact="influenza" post="Oseltamivir and zanamivir are neuraminidase inhibitors, used for treating"/>
 <result pre="influenza Oseltamivir and zanamivir are neuraminidase inhibitors, used for treating" exact="influenza" post="by shortening the duration of the disease, relieving the"/>
 <result pre="relieving the symptoms and reducing the complications and transmission of" exact="influenza" post="[1]. Neuraminidase inhibition prevents the virus from spreading within"/>
 <result pre="use, no major neuropsychiatric adverse events are described. Headache (9-23%)," exact="migraine" post="(&amp;lt;3%), and paresthesia (&amp;lt;3%) are occasionally reported. Foscarnet (trisodium"/>
 <result pre="investigational pyrophosphate analog is increasingly used to treat refractory cytomegalovirus" exact="retinitis" post="and mucocutaneous herpes simplex virus infections in immunocompromised patients."/>
 <result pre="is increasingly used to treat refractory cytomegalovirus retinitis and mucocutaneous" exact="herpes simplex" post="virus infections in immunocompromised patients. Foscarnet has been reported"/>
 <result pre="to hypocalcemia [9]. Neuropsychiatric effects of antiviral therapy for chronic" exact="hepatitis" post="B (CHB) Chronic hepatitis B requires long-term treatment with"/>
 <result pre="effects of antiviral therapy for chronic hepatitis B (CHB) Chronic" exact="hepatitis" post="B requires long-term treatment with antiviral drugs, so side"/>
 <result pre="the drugs used. Antiviral agents indicated for the treatment of" exact="hepatitis" post="B include lamivudine, telbivudine, and entecavir (classified as nucleoside"/>
 <result pre="tenofovir alafenamide [10]. Lamivudine and telbivudine have been associated with" exact="myopathy" post="and peripheral neuropathy, with the incidence of these effects"/>
 <result pre="[10]. Lamivudine and telbivudine have been associated with myopathy and" exact="peripheral neuropathy," post="with the incidence of these effects being similar across"/>
 <result pre="another study, three of six patients with lamivudine or telbivudine足associated" exact="myopathy" post="had a complaint of numbness in the distal end"/>
 <result pre="complaint of numbness in the distal end of limbs, suggesting" exact="peripheral neuropathy." post="The presence of neuropathy was confirmed by the electrophysiological"/>
 <result pre="distal end of limbs, suggesting peripheral neuropathy. The presence of" exact="neuropathy" post="was confirmed by the electrophysiological studies and nerve biopsies"/>
 <result pre="monotherapy in clinical trials, 10 (0.28%) were reported to have" exact="peripheral neuropathy" post="compared to nine of 48 (18.75%) patients who received"/>
 <result pre="in clinical trials, 10 (0.28%) were reported to have peripheral" exact="neuropathy" post="compared to nine of 48 (18.75%) patients who received"/>
 <result pre="of nucleoside analogues (NAs), but they are not specific for" exact="myopathy" post="and may be associated with strenuous exercise and many"/>
 <result pre="1-10% of patients treated with entecavir suffer from insomnia. Entecavir足-associated" exact="myopathy" post="and peripheral neuropathy cases were very rarely reported in"/>
 <result pre="patients treated with entecavir suffer from insomnia. Entecavir足-associated myopathy and" exact="peripheral neuropathy" post="cases were very rarely reported in the literature. Patients"/>
 <result pre="treated with entecavir suffer from insomnia. Entecavir足-associated myopathy and peripheral" exact="neuropathy" post="cases were very rarely reported in the literature. Patients"/>
 <result pre="reported in the literature. Patients receiving entecavir presenting with severe" exact="lactic acidosis," post="complain of weakness, reduced general physical condition, and impaired"/>
 <result pre="and impaired consciousness [10]. Neuropsychiatric effects of antiviral therapy in" exact="hepatitis" post="C The management of patients with hepatitis C is"/>
 <result pre="antiviral therapy in hepatitis C The management of patients with" exact="hepatitis" post="C is very complex. Psychiatric symptoms during antiviral therapy"/>
 <result pre="symptoms during antiviral therapy are reported in 30-40% of chronic" exact="hepatitis" post="C (CHC) patients treated for 6-12 months and are"/>
 <result pre="pegylated interferon and ribavirin was the mainstay of treatment for" exact="hepatitis" post="C infection until the approval of direct-acting antivirals. The"/>
 <result pre="direct-acting antiviral (DAA) regimens has dramatically changed the approach to" exact="hepatitis" post="C virus (HCV) infection management. New antivirals have been"/>
 <result pre="effects of DAAs may be more pronounced in patients with" exact="liver cancer," post="as one study found an association between their use"/>
 <result pre="course of treatment with a sofosbuvir (SOF)-based regimen, patients with" exact="cirrhosis" post="exhibited an increase in extra-slow EEG activity and a"/>
 <result pre="and usually transient as a result of DAA treatment for" exact="hepatitis" post="C, but further research is required in larger patient"/>
 <result pre="a chronic toxidrome reminiscent of inherited mitochondrial disorders, which include" exact="peripheral neuropathy," post="myopathy [27]. All drugs of this category have been"/>
 <result pre="toxidrome reminiscent of inherited mitochondrial disorders, which include peripheral neuropathy," exact="myopathy" post="[27]. All drugs of this category have been associated"/>
 <result pre="varies. Didanosine and stavudine have been more strongly associated with" exact="peripheral neuropathy," post="whereas zidovudine has more commonly been associated with myopathy"/>
 <result pre="peripheral neuropathy, whereas zidovudine has more commonly been associated with" exact="myopathy" post="and myelotoxicity. The pro-drug tenofovir alafenamide, which leads to"/>
 <result pre="first-line treatment since the 1990s. It has been associated with" exact="peripheral neuropathy" post="attributed to depletion of mitochondrial DNA by the mechanism"/>
 <result pre="treatment since the 1990s. It has been associated with peripheral" exact="neuropathy" post="attributed to depletion of mitochondrial DNA by the mechanism"/>
 <result pre="mechanism that is common for all NRTIs. The risk of" exact="neuropathy" post="seems to be dependent upon the total cumulative exposure"/>
 <result pre="zidovudine discontinuation [28]. In contemporary clinical settings, the incidence of" exact="peripheral neuropathy" post="or myopathy during treatment with zidovudine could be managed"/>
 <result pre="discontinuation [28]. In contemporary clinical settings, the incidence of peripheral" exact="neuropathy" post="or myopathy during treatment with zidovudine could be managed"/>
 <result pre="In contemporary clinical settings, the incidence of peripheral neuropathy or" exact="myopathy" post="during treatment with zidovudine could be managed by drug"/>
 <result pre="disiproxil fumarate is the first-line treatment for both HIV and" exact="hepatitis" post="B virus (HBV) infection, due to its similar efficacy"/>
 <result pre="and significantly improved safety profile compared to other NRTIs. Peripheral" exact="neuropathy" post="is less common with tenofovir compared to other NRTIs"/>
 <result pre="although it does occur. Eight percent of participants developed sensory" exact="neuropathy" post="in a South African cohort of 120 treatment-naive individuals"/>
 <result pre="the drug. Nevirapine has, however, been associated with hepatotoxicity and" exact="peripheral neuropathy," post="similar to nucleoside reverse transcriptase inhibitors, as evidenced by"/>
 <result pre="CYP3A4 metabolism for inactivation. They have been associated with a" exact="lipodystrophy" post="syndrome characterized by insulin resistance, dyslipidemia, central adiposity, and"/>
 <result pre="disease [40]. Prolonged use may contribute to the development of" exact="dementia" post="by promoting the pathogenesis of cerebral small vessel disease"/>
 <result pre="of an NRTI by a fusion inhibitor may partially attenuate" exact="peripheral neuropathy" post="and myopathy without compromising treatment efficacy [50]. Further research"/>
 <result pre="an NRTI by a fusion inhibitor may partially attenuate peripheral" exact="neuropathy" post="and myopathy without compromising treatment efficacy [50]. Further research"/>
 <result pre="by a fusion inhibitor may partially attenuate peripheral neuropathy and" exact="myopathy" post="without compromising treatment efficacy [50]. Further research is, however,"/>
 <result pre="correct electrolyte abnormalities. Ribavirin Depressed mood, irritability, anxiety, sleep disturbances," exact="sexual dysfunction" post="- gradual onset Unclear Consider treatment discontinuation (direct-acting antiviral"/>
 <result pre="effects are attributable to ribavirin alone. Direct-acting antiviral agents for" exact="hepatitis" post="C Depression, insomnia, irritability, anxiety Unclear Address symptoms if"/>
 <result pre="ribavirin use may exacerbated NPAEs. Nucleoside / Nucleotide analogues Peripheral" exact="neuropathy" post="and myopathy. Idiosyncratic manic or psychotic reactions to treatment"/>
 <result pre="zidovudine) compared to the ones currently recommended (lamivudine, tenofovir) Peripheral" exact="neuropathy" post="is more pronounced with increased duration of exposure and"/>
 <result pre="dosing at night. In patients with a psychiatric history or" exact="substance abuse," post="alternative agents may be preferred. Psychotropic effects likely present"/>
 <result pre="may predispose to the development of dementia, cerebrovascular disease. Peripheral" exact="neuropathy" post="Direct psychotropic effects unlikely, may cause NPAEs via promoting"/>
 <result pre="exist. References References 1Neuropsychiatric events in an adult patient with" exact="influenza" post="a (H3N2) treated with oseltamivir (Tamiflu): a case reportBMC"/>
 <result pre="Endocrinol MetabJacobsonMAGambertoglioJGAweekaFTCauseyDMPortaleAA113011357219911827127 10Adverse effects of oral antiviral therapy in chronic" exact="hepatitis" post="BWorld J HepatolKayaaslanBGunerR2272419201728261380 11Longitudinal analysis of the associations between"/>
 <result pre="pegylated interferon-alpha and ribavirin therapy in Iranian patients with chronic" exact="hepatitis" post="C: a meta-analysisExp Ther MedDavoodiLMasoumBMoosazadehMJafarpourHHaghshenasMRMousaviT97197816201830116347 14A case report of"/>
 <result pre="symptoms following direct-acting antiviral and ribavirin combination therapy for chronic" exact="hepatitis" post="C in a patient with innate anxietyBMC GastroenterolSakamakiAKamimuraKFukuiNet al.8519201931195993"/>
 <result pre="anxietyBMC GastroenterolSakamakiAKamimuraKFukuiNet al.8519201931195993 15Neuropsychiatric toxicity of antiviral treatment in chronic" exact="hepatitis" post="CDig DisFontanaRJ10711618200011279329 16Efficacy and tolerability of interferon-free regimen for"/>
 <result pre="HCV infectionExp Ther MedTakedaKNoguchiRNamisakiTet al.2743275016201830210615 17Neuropsychiatric performance and treatment of" exact="hepatitis" post="C with direct-acting antivirals: a prospective studyBMJ Open GastroenterolVolpatoSMontagneseSZanettoAet"/>
 <result pre="boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic" exact="hepatitis" post="C genotype 1: a combined analysis of 3 phase"/>
 <result pre="III results of Boceprevir in treatment naive patients with chronic" exact="hepatitis" post="C genotype 1Liver IntMannsMPMarkovaAACalle SerranoBCornbergM273132201222212568 21Efficacy and safety outcomes"/>
 <result pre="SerranoBCornbergM273132201222212568 21Efficacy and safety outcomes of sofosbuvir-based treatment regimens for" exact="hepatitis" post="C virus-infected patients with or without cirrhosis from phase"/>
 <result pre="treatment regimens for hepatitis C virus-infected patients with or without" exact="cirrhosis" post="from phase III clinical trialsTher Clin Risk ManagYangY-MChoiEJ47749713201728442915 22Neurologic"/>
 <result pre="phase III clinical trialsTher Clin Risk ManagYangY-MChoiEJ47749713201728442915 22Neurologic manifestations of" exact="hepatitis" post="C virus infectionClin Liver DisIrianaSCurryMPAfdhalNH53554221201728689591 23Impact of treatment with"/>
 <result pre="treatment with direct-acting antivirals on anxiety and depression in chronic" exact="hepatitis" post="CPLoS OneGallachMVergaraMda CostaJPet al.208112132018 24The next generation of the"/>
 <result pre="vs. single (zidovudine) nucleoside reverse transcriptase inhibitorsHIV MedReissPCasulaMde RondeAWeverlingGJGoudsmitJLangeJMA11145200414731163 28Prevalent" exact="neuropathy" post="in a cohort of HIV-infected Kenyan sex workers using"/>
 <result pre="reporting system in NigeriaPerspect Clin ResAguKAOparahAC1171244201323833736 30Clinical diagnosis of sensory" exact="neuropathy" post="in HIV patients treated with tenofovir: a 6-month follow-up"/>
 <result pre="GriensvenJZachariahRRasschaertFMugaboJAtteEFReidT148153104201019732926 40Brain injury caused by HIV protease inhibitors: role of" exact="lipodystrophy" post="and insulin resistanceAntiviral ResGuptaSKnightAGLossoBYIngramDKKellerJNBruce-KellerAJ192995201222580130 41Potential drug-drug interactions in HIV-perinatally"/>
</results>
